The Working Group Report from the ILTS Transplant Oncology Consensus Conference in 2020 underscored that the selection process should consider tumor biology (including AFP), tumor size, number of tumors, probability of survival, transplant benefit, organ availability, waiting list composition, and allocation priorities (43). Here, AFP is linked to neoplasm.